Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1152-1168

  Malgras, Brice ^a   Pautrat, Karine ^a   Dray, Xavier ^b,c   Pasquier, Pierre ^a   Valleur, Patrice ^a,c   Pocard, Marc ^a,c   Soyer, Philippe ^b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c France   (France)

Author keywords

Crohn s disease; Fibrotic; Management; Stenosis

Indexed keywords

GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL SURGERY; ADVERSE EFFECTS; ANIMAL; CROHN DISEASE; DIAGNOSTIC IMAGING; FIBROSIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTESTINAL OBSTRUCTION; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME;

ANIMALS; COMBINED MODALITY THERAPY; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ENDOSCOPY, GASTROINTESTINAL; FIBROSIS; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL OBSTRUCTION; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84937965860     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3421-y     Document Type: Review

References (157)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.
2. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62:1072–1084.
3. Malgras B, Soyer P, Boudiaf M, et al. Accuracy of imaging for predicting operative approach in Crohn’s disease. Br J Surg. 2012;99:1011–1020.
4. Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease–review of the literature. Int J Colorectal Dis. 2010;25:1149–1157.
5. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4:63–101.
6. De’ Angelis N, Carra MC, Borrelli O, et al. Short- and long-term efficacy of endoscopic balloon dilation in Crohn’s disease strictures. World J Gastroenterol. 2013;19:2660–2667.
7. Fornasa F, Benassuti C, Benazzato L. Role of magnetic resonance enterography in differentiating between fibrotic and active inflammatory small bowel stenosis in patients with crohn’s disease. J Clin Imaging Sci. 2011;1:35.
8. Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1457–1464.
9. Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438.
10. Soyer P, Boudiaf M, Sirol M, et al. Suspected anastomotic recurrence of Crohn disease after ileocolic resection: evaluation with CT enteroclysis. Radiology. 2010;254:755–764.
11. Regan MC, Flavin BM, Fitzpatrick JM, O’Connell PR. Stricture formation in Crohn’s disease: the role of intestinal fibroblasts. Ann Surg. 2000;231:46–50.
12. Limketkai BN, Bayless TM. Editorial: can stenosis in ileal Crohn’s disease be prevented by current therapy? Am J Gastroenterol. 2013;108:1755–1756.
13. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol. 2008;24:462–468.
14. Johnson LA, Rodansky ES, Sauder KL, et al. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts. Inflamm Bowel Dis. 2013;19:891–903.
15. Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatol Baltim Md. 2008;47:1394–1400.
16. Otte J-M, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology. 2003;124:1866–1878.
17. Graham MF. Pathogenesis of intestinal strictures in Crohn’s disease-an update. Inflamm Bowel Dis. 1995;1:220–227.
18. Coelho J, Soyer P, Pautrat K, et al. Management of ileal stenosis in patients with Crohn’s disease. Gastroenterol Clin Biol. 2009;33:F75–F81.
19. Maglinte DD. Small bowel imaging—a rapidly changing field and a challenge to radiology. Eur Radiol. 2006;16:967–971.
20. Soyer P, Boudiaf M, Fishman EK, et al. Imaging of malignant neoplasms of the mesenteric small bowel: new trends and perspectives. Crit Rev Oncol Hematol. 2011;80:10–30.
21. Maglinte DD, Sandrasegaran K, Chiorean M, Dewitt J, McHenry L, Lappas JC. Radiologic investigations complement and add diagnostic information to capsule endoscopy of small-bowel diseases Am J Roentgenol. 2007;189:306–312.
22. Khalife S, Soyer P, Alatawi A, et al. Obscure gastrointestinal bleeding: preliminary comparison of 64-section CT enteroclysis with video capsule endoscopy. Eur Radiol. 2011;21:79–86.
23. Masselli G, Casciani E, Polettini E, Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn’s disease. Eur Radiol. 2008;18:438–447.
24. Maccioni F, Bruni A, Viscido A, et al. MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology. 2006;238:517–530.
25. Ebinger M, Rieber A, Leidl R. Cost-effectiveness of magnetic resonance imaging and enteroclysis in the diagnostic imaging of Crohn’s disease. Int J Technol Assess Health Care. 2002;18:711–717.
26. Mackalski BA, Bernstein CN. New diagnostic imaging tools for inflammatory bowel disease. Gut. 2006;55:733–741.
27. Voderholzer WA, Beinhoelzl J, Rogalla P, et al. Small bowel involvement in Crohn’s disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut. 2005;54:369–373.
28. Turetschek K, Schober E, Wunderbaldinger P, et al. Findings at helical CT-enteroclysis in symptomatic patients with crohn disease: correlation with endoscopic and surgical findings. J Comput Assist Tomogr. 2002;26:488–492.
29. Vogel J, da Luz Moreira A, Baker M, et al. CT enterography for Crohn’s disease: accurate preoperative diagnostic imaging. Dis Colon Rectum. 2007;50:1761–1769.
30. Maglinte DD, Bender GN, Heitkamp DE, Lappas JC, Kelvin FM. Multidetector-row helical CT enteroclysis. Radiol Clin North Am. 2003;41:249–262.
31. Boudiaf M, Soyer P, Terem C, Pelage JP, Maissiat E, Rymer R. Ct evaluation of small bowel obstruction. Radiographics. 2001;21:613–624.
32. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011;17:1073–1080.
33. Pilleul F, Godefroy C, Yzebe-Beziat D, Dugougeat-Pilleul F, Lachaux A, Valette PJ. Magnetic resonance imaging in Crohn’s disease. Gastroenterol Clin Biol. 2005;29:803–808.
34. Rodriguez P, Mendez R, Matute F, Hernandez P, Mendoza JL. Imaging Crohn disease: mR enterography. J Comput Assist Tomogr. 2014;38:219–227.
35. Negaard A, Paulsen V, Sandvik L, et al. A prospective randomized comparison between two MRI studies of the small bowel in Crohn’s disease, the oral contrast method and MR enteroclysis. Eur Radiol. 2007;17:2294–2301.
36. Pariente B, Peyrin-Biroulet L, Cohen L, Zagdanski AM, Colombel JF. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. Am J Roentgenol. 2011;197:42–49.
37. Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–2284.
38. Lenze F, Wessling J, Bremer J, et al. Detection and differentiation of inflammatory versus fibromatous Crohn’s disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis. 2012;18:2252–2260.
39. Bickelhaupt S, Froehlich JM, Cattin R, et al. Differentiation between active and chronic Crohn’s disease using MRI small-bowel motility examinations—initial experience. Clin Radiol. 2013;68:1247–1253.
40. Maccioni F, Patak MA, Signore A, Laghi A. New frontiers of MRI in Crohn’s disease: motility imaging, diffusion-weighted imaging, perfusion MRI, MR spectroscopy, molecular imaging, and hybrid imaging (PET/MRI). Abdom Imaging. 2012;37:974–982.
41. Froehlich JM, Waldherr C, Stoupis C, Erturk SM, Patak MA. MR motility imaging in Crohn’s disease improves lesion detection compared with standard MR imaging. Eur Radiol. 2010;20:1945–1951.
42. Cullmann JL, Bickelhaupt S, Froehlich JM, et al. MR imaging in Crohn’s disease: correlation of MR motility measurement with histopathology in the terminal ileum. Neurogastroenterol Motil. 2013;25:749-e577.
43. Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984–993.
44. Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol. 2007;102:2541–2550.
45. Adler J, Punglia DR, Dillman JR, et al. Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn’s disease. Inflamm Bowel Dis. 2012;18:849–856.
46. Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn’s disease. Int J Colorectal Dis. 2005;20:1–8.
47. Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Outcome of medical treatment of stricturing and penetrating Crohn’s disease: a retrospective study. Inflamm Bowel Dis. 2010;16:1187–1194.
48. Sorrentino D. Role of biologics and other therapies in stricturing Crohn’s disease: what have we learnt so far? Digestion. 2008;77:38–47.
49. Sailer J, Peloschek P, Reinisch W, Vogelsang H, Turetschek K, Schima W. Anastomotic recurrence of Crohn’s disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol. 2008;18:2512–2521.
50. Keuchel M. Double balloon (push-and-pull) enteroscopy: breakthrough in the management of small intestinal strictures in Crohn’s disease? Eur J Gastroenterol Hepatol. 2007;19:523–525.
51. Yamamoto H, Kita H. Double-balloon endoscopy. Curr Opin Gastroenterol. 2005;21:573–577.
52. Tharian B, Caddy G, Tham TC. Enteroscopy in small bowel Crohn’s disease: a review. World J Gastrointest Endosc. 2013;5:476–486.
53. Caunedo-Alvarez A, Romero-Vazquez J, Herrerias-Gutierrez J-M. Patency and Agile capsules. World J Gastroenterol. 2008;14:5269–5273.
54. Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy. 2009;41:618–637.
55. Wiarda BM, Mensink PBF, Heine DGN, et al. Small bowel Crohn’s disease: mR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. Abdom Imaging. 2012;37:397–403.
56. Soyer P. Obscure gastrointestinal bleeding: difficulties in comparing CT enterography and video capsule endoscopy. Eur Radiol. 2012;22:1167–1171.
57. D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology. 1997;112:1475–1481.
58. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.
59. Papay P, Ignjatovic A, Karmiris K, et al. Optimising monitoring in the management of Crohn’s disease: a physician’s perspective. J Crohns Colitis. 2013;7:653–669.
60. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–576.
61. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524–534.
62. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56–66.
63. Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.
64. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut. 2005;54:237–241.
65. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030–1038.
66. Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn’s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134:565–572.
67. Riello L, Talbotec C, Garnier-Lengliné H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–2143.
68. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60:930–936.
69. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–987.
70. Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastro Enterol Belg. 2007;70:15–19.
71. Pelletier A-L, Kalisazan B, Wienckiewicz J, et al. Infliximab treatment for symptomatic Crohn’s disease strictures. Aliment Pharmacol Ther. 2009;29:279–285.
72. Holtmann M, Wanitschke R, Helisch A, et al. Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn’s disease. Z Gastroenterol. 2003;41:11–17.
73. Pallotta N, Barberani F, Hassan N-A, et al. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14:1885–1890.
74. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–508.
75. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630.
76. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265–274.
77. Sorrentino D, Avellini C, Beltrami CA, et al. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease. Int J Colorectal Dis. 2006;21:276–281.
78. Sorrentino D, Terrosu G, Vadalà S, et al. Fibrotic strictures and anti-TNF-alpha therapy in Crohn’s disease. Digestion. 2007;75:22–24.
79. Knapp AB, Mirsky FJ, Dillon EH, et al. Successful infliximab therapy for a duodenal stricture caused by Crohn’s disease. Inflamm Bowel Dis. 2005;11:1123–1125.
80. Sorrentino D, Terrosu G, Avellini C, et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167:1804–1807.
81. Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn’s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012;18:2225–2231.
82. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.
83. Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138–1144.
84. Cao Y, Gao F, Liao C, et al. Meta-analysis of medical treatment and placebo treatment for preventing postoperative recurrence in Crohn’s disease (CD). Int J Colorectal Dis. 2009;24:509–520.
85. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23:1213–1221.
86. Gustavsson A, Magnuson A, Blomberg B, et al. Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:430–437.
87. Scimeca D, Mocciaro F, Cottone M, et al. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn’s disease strictures. Dig Liver Dis. 2011;43:121–125.
88. Thomas-Gibson S, Brooker JC, Hayward CMM, et al. Colonoscopic balloon dilation of Crohn’s strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003;15:485–488.
89. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–656.
90. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.
91. Hagel AF, Hahn A, Dauth W, et al. Outcome and complications of endoscopic balloon dilatations in various types of ileocaecal and colonic stenosis in patients with Crohn’s disease. Surg Endosc. 2014;10:2966–2972.
92. Mueller T, Rieder B, Bechtner G, et al. The response of Crohn’s strictures to endoscopic balloon dilation. Aliment Pharmacol Ther. 2010;31:634–639.
93. East JE, Brooker JC, Rutter MD, et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn’s strictures. Clin Gastroenterol Hepatol. 2007;5:1065–1069.
94. Di Nardo G, Oliva S, Passariello M, et al. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn’s disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc. 2010;72:1201–1208.
95. Thienpont C, D’Hoore A, Vermeire S, et al. Long-term outcome of endoscopic dilatation in patients with Crohn’s disease is not affected by disease activity or medical therapy. Gut. 2010;59:320–324.
96. Atreja A, Aggarwal A, Dwivedi S, et al. Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn’s disease strictures. J Crohns Colitis. 2014;8:392–400.
97. Gustavsson A, Magnuson A, Blomberg B, et al. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn’s disease. Aliment Pharmacol Ther. 2012;36:151–158.
98. Endo K, Takahashi S, Shiga H, et al. Short and long-term outcomes of endoscopic balloon dilatation for Crohn’s disease strictures. World J Gastroenterol. 2013;19:86–91.
99. Raedler A, Peters I, Schreiber S. Treatment with azathioprine and budesonide prevents reoccurence of ileocolonic stenoses after endoscopic dilatation in Crohn’s disease. Gastroenterology 1997;A:1067.
100. Ferlitsch A, Reinisch W, Püspök A, et al. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn’s disease strictures. Endoscopy. 2006;38:483–487.
101. Honzawa Y, Nakase H, Matsuura M, et al. Prior use of immunomodulatory drugs improves the clinical outcome of endoscopic balloon dilation for intestinal stricture in patients with Crohn’s disease. Dig Endosc. 2013;25:535–543.
102. Ono Y, Hirai F, Matsui T, et al. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn’s disease. Dig Endosc. 2012;24:432–438.
103. Sabaté J-M, Villarejo J, Bouhnik Y, et al. Hydrostatic balloon dilatation of Crohn’s strictures. Aliment Pharmacol Ther. 2003;18:409–413.
104. Griffiths AM. Enteral nutrition in the management of Crohn’s disease. J Parenter Enteral Nutr. 2005;29:S108–S112.
105. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum. 2000;43:1141–1145.
106. Iesalnieks I, Kilger A, Glass H, et al. Intraabdominal septic complications following bowel resection for Crohn’s disease: detrimental influence on long-term outcome. Int J Colorectal Dis. 2008;23:1167–1174.
107. Froehlich F, Juillerat P, Pittet V, et al. Maintenance of surgically induced remission of Crohn’s disease. Digestion. 2007;76:130–135.
108. Couckuyt H, Gevers AM, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn’s strictures: a prospective longterm analysis. Gut. 1995;36:577–580.
109. Hoffmann JC, Heller F, Faiss S, et al. Through the endoscope balloon dilation of ileocolonic strictures: prognostic factors, complications, and effectiveness. Int J Colorectal Dis. 2008;23:689–696.
110. Brochard C, Siproudhis L, Wallenhorst T, et al. Anorectal stricture in 102 patients with Crohn’s disease: natural history in the era of biologics. Aliment Pharmacol Ther. 2014;40:796–803.
111. Linares L, Moreira LF, Andrews H, et al. Natural history and treatment of anorectal strictures complicating Crohn’s disease. Br J Surg. 1988;75:653–655.
112. Lewis RT, Maron DJ. Anorectal Crohn’s disease. Surg Clin North Am. 2010;90:83–97.
113. Galandiuk S, Kimberling J, Al-Mishlab TG, et al. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg. 2005;241:796–801.
114. Bouguen G, Siproudhis L, Bretagne J-F, et al. Nonfistulizing perianal Crohn’s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16:1431–1442.
115. Erkelens GW, van Deventer SJH. Endoscopic treatment of strictures in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2004;18:201–207.
116. Geiger TM, Miedema BW, Tsereteli Z, et al. Stent placement for benign colonic stenosis: case report, review of the literature, and animal pilot data. Int J Colorectal Dis. 2008;23:1007–1012.
117. Thomas T, Abrams KR, Subramanian V, et al. Esophageal stents for benign refractory strictures: a meta-analysis. Endoscopy. 2011;43:386–393.
118. Attar A, Maunoury V, Vahedi K, et al. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn’s disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012;18:1849–1854.
119. Branche J, Attar A, Vernier-Massouille G, et al. Extractible self-expandable metal stent in the treatment of Crohn’s disease anastomotic strictures. Endoscopy. 2012;44:E325–E326.
120. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224:563–571.
121. Heuman R, Boeryd B, Bolin T, et al. The influence of disease at the margin of resection on the outcome of Crohn’s disease. Br J Surg. 1983;70:519–521.
122. McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52:919–927.
123. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665–672.
124. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–963.
125. Sampietro GM, Cristaldi M, Porretta T, et al. Early perioperative results and surgical recurrence after strictureplasty and miniresection for complicated Crohn’s disease. Dig Surg. 2000;17:261–267.
126. Shore G, Gonzalez QH, Bondora A, et al. Laparoscopic vs conventional ileocolectomy for primary Crohn disease. Arch Surg. 2003;138:76–79.
127. Simillis C, Purkayastha S, Yamamoto T, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn’s disease. Dis Colon Rectum. 2007;50:1674–1687.
128. Scarpa M, Angriman I, Barollo M, et al. Role of stapled and hand-sewn anastomoses in recurrence of Crohn’s disease. Hepatogastroenterology. 2004;51:1053–1057.
129. Tilney HS, Constantinides VA, Heriot AG, et al. Comparison of laparoscopic and open ileocecal resection for Crohn’s disease: a metaanalysis. Surg Endosc. 2006;20:1036–1044.
130. Lesperance K, Martin MJ, Lehmann R, et al. National trends and outcomes for the surgical therapy of ileocolonic Crohn’s disease: a population-based analysis of laparoscopic vs. open approaches. J Gastrointest Surg. 2009;13:1251–1259.
131. Milsom JW, Hammerhofer KA, Böhm B, et al. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn’s disease. Dis Colon Rectum. 2001;44:1–8.
132. Maartense S, Dunker MS, Slors JFM, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn’s disease: a randomized trial. Ann Surg. 2006;243:143–149.
133. Shaffer VO, Wexner SD. Surgical management of Crohn’s disease. Langenbecks Arch Surg. 2013;398:13–27.
134. Futami K, Arima S. Role of strictureplasty in surgical treatment of Crohn’s disease. J Gastroenterol. 2005;40:35–39.
135. Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn’s disease: quality of life after surgical therapy. Int J Colorectal Dis. 2001;16:81–87.
136. Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn’s disease. J Am Coll Surg. 2001;192:330–337.
137. Von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum. 2007;50:839–855.
138. Campbell L, Ambe R, Weaver J, et al. Comparison of conventional and nonconventional strictureplasties in Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2012;55:714–726.
139. Fearnhead NS, Chowdhury R, Box B, et al. Long-term follow-up of strictureplasty for Crohn’s disease. Br J Surg. 2006;93:475–482.
140. Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 2007;9:686–694.
141. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50:1968–1986.
142. Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn’s disease. J Surg Res. 2004;117:71–78.
143. Sampietro GM, Sartani A, Danelli P, et al. Strictureplasty in the surgical treatment of complicated Crohn’s disease. Ann Ital Chir. 2003;74:659–663.
144. Tonelli F, Fedi M, Paroli GM, et al. Indications and results of side-to-side isoperistaltic strictureplasty in Crohn’s disease. Dis Colon Rectum. 2004;47:494–501.
145. Shatari T, Clark MA, Yamamoto T, et al. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn’s disease. Colorectal Dis. 2004;6:438–441.
146. Poggioli G, Laureti S, Pierangeli F, et al. A new model of strictureplasty for multiple and long stenoses in Crohn’s ileitis: side-to-side diseased to disease-free anastomosis. Dis Colon Rectum. 2003;46:127–130.
147. Tichansky D, Cagir B, Yoo E, et al. Strictureplasty for Crohn’s disease: meta-analysis. Dis Colon Rectum. 2000;43:911–919.
148. Ambe R, Campbell L, Cagir B. A comprehensive review of strictureplasty techniques in Crohn’s disease: types, indications, comparisons, and safety. J Gastrointest Surg. 2012;16:209–217.
149. Yaffe BH, Korelitz BI. Prognosis for nonoperative management of small-bowel obstruction in Crohn’s disease. J Clin Gastroenterol. 1983;5:211–215.
150. Oberhuber G, Stangl PC, Vogelsang H, et al. Significant association of strictures and internal fistula formation in Crohn’s disease. Virchows Arch Int J Pathol. 2000;437:293–297.
151. Miehsler W, Reinisch W, Kazemi-Shirazi L, et al. Infliximab: lack of efficacy on perforating complications in Crohn’s disease. Inflamm Bowel Dis. 2004;10:36–40.
152. Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:205–209.
153. Ng SC, Kamm MA. Fulminant Crohn’s colitis: when only an antibody will do. Inflamm Bowel Dis. 2007;13:971–974.
154. Clark M, Colombel J-F, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology. 2007;133:312–339.
155. Roy P, Kumar D. Strictureplasty. Br J Surg. 2004;91:1428–1437.
156. Jobanputra S, Weiss EG. Strictureplasty. Clin Colon Rectal Surg. 2007;20:294–302.
157. Travis SPL, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55:i16–i35.